Arturo LoAIza-Bonilla, MD MSEd

Arturo LoAIza-Bonilla: Solving the Clinical Trial Enrollment Paradox Using AI and Big Data - OncoDaily Arturo LoAIza-Bonilla: Solving the Clinical Trial Enrollment Paradox Using AI and Big Data / Arturo Loaiza-Bonilla, ASCO, cancer, OncoDaily, Oncology

Solving the Clinical Trial Enrollment Paradox Using AI and Big Data - Arturo LoAIza-Bonilla

@drbonillaonc.bsky.social

oncodaily.com/voices/artur...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Figure 1. Moravec’s Paradox in Health Care.

Perspective by Arturo Loaiza-Bonilla, MD, MSEd, FACP, and Scott Penberthy, PhD : Harnessing Moravec’s Paradox in Health Care: A New Era of Collaborative Intelligence nejm.ai/4jSWaVV

@drbonillaonc.bsky.social #AI #MedSky #MLSky

#asco25 joint @ascocancer.bsky.social @myesmo.bsky.social session on “Biomarker-driven Therapeutics: Translating Innovation into Practice” @drbonillaonc.bsky.social

Red lens sunglasses can enhance contrast and depth perception, may also reduce eye fatigue by filtering certain wavelengths and improving visual comfort. After so much screen time in preparation for #ASCO25 this really helps! See you in Chicago!! @ASCO @mystlukes @americancancersoc.bsky.social

Yan Leyfman: Performance Evaluation of an AI-powered System For Clinical Trial Eligibility Using mCODE Data Standards - OncoDaily Yan Leyfman: Performance Evaluation of an AI-powered System For Clinical Trial Eligibility Using mCODE Data Standards / and Cagatay Culcuoglu, Arturo

Performance Evaluation of an AI-powered System for Clinical Trial Eligibility Using mCODE Data Standards - Yan Leyfman
@yleyfman.bsky.social
@drbonillaonc.bsky.social
@massive-bio.bsky.social

oncodaily.com/blog/yan-ley...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AI

ASCO/ESMO Joint Session at ASCO25 Will Highlight Key Issues in Biomarker-Driven Therapeutics dailynews.ascopubs.org/do/asco-esmo...

Filming day at St. Luke’s! 🎥
From clinical trials to AI-powered care, we’re showcasing how we fight cancer with heart and innovation. 🚀

16 hospitals.
Robotic surgery.
Advanced radiation.
Multiomics + bi-specifics.
The most wired health system in the U.S.
All for you.

#StLukesProud

Driving Knowledge to Action: Building a Better Future With Artificial Intelligence–Enabled Multidisciplinary Oncology | American Society of Clinical Oncology Educational Book ascopubs.org/doi/full/10.... #ASCO25 @drbonillaonc.bsky.social

Arturo LoAIza-Bonilla: How AI and Digital Platforms are Transforming Patient Adherence and Real-Time Decision Support - OncoDaily Arturo LoAIza-Bonilla: How AI and Digital Platforms are Transforming Patient Adherence and Real-Time Decision Support / AI, Arturo Loaiza-Bonilla, ASCO,

How AI and Digital Platforms are Transforming Patient Adherence and Real-Time Decision Support - Arturo LoAIza-Bonilla
@drbonillaonc.bsky.social

oncodaily.com/blog/arturo-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AI #ASCO25

Driving Knowledge to Action: Building a Better Future With Artificial Intelligence–Enabled Multidisciplinary Oncology Artificial intelligence (AI) is transforming multidisciplinary oncology at an unprecedented pace, redefining how clinicians detect, classify, and treat cancer. From earlier and more accurate diagnoses...

Driving Knowledge to Action: Building a Better Future With Artificial Intelligence–Enabled Multidisciplinary Oncology | American Society of Clinical Oncology Educational Book ascopubs.org/doi/full/10....

Thrilled to see my latest article featured in the Spring 2025 issue of llOncolytics Today! 🌟 “Closing the Gaps in Oncology: How AI and Digital Platforms are Transforming Patient Adherence and Real-Time Decision Support”
#ASCO25.

See you in Chicago!

#PrescreeningHubs

Moravec’s paradox also discussed in context of AI & healthcare by @pmarca.tweet.pub in recent thoughtful @a16z.bsky.social pcast, as I wrote about here: timmermanreport.com/2025/02/the-...

Harnessing Moravec’s Paradox in Health Care: A New Era of Collaborative Intelligence Artificial intelligence excels at complex data analytics, yet struggles with nuanced, sensorimotor tasks that humans perform almost effortlessly — a dichotomy encapsulated by Moravec’s paradox. By ...

A good discussion of Moravec's paradox in healthcare
@NEJM_AI
ai.nejm.org/doi/full/10....

Thrilled! Our @ai.nejm.org NEJM AI perspective “Harnessing Moravec’s Paradox in Health Care” - is now live. Grateful for brilliant co-author & friend Scott Penberthy (@scottpenberthy) of @GoogleCloud. Onward to truly collaborative intelligence! 🔗 ai.nejm.org/stoken/defau...

Arturo LoAIza-Bonilla: Full day of CME discussing the top research from ASCOGI25 - OncoDaily Arturo LoAIza-Bonilla: Full day of CME discussing the top research from ASCOGI25 / American Society of Clinical Oncology, Arturo Loaiza-Bonilla, ASCO,

Full day of CME discussing the top research from ASCOGI25 - @drbonillaonc.bsky.social
@ascocancer.bsky.social

oncodaily.com/url/269641

#OncoDaily #Oncology #Cancer #Health #Medicine #ASCOGI25

Investigating the Emergence of Artificial Intelligence on Oncologic Practice As artificial intelligence has arrived in the oncology field, experts discuss how this new technology can have implications for transforming clinical practice.

www.cancernetwork.com/view/investi... - Dr. Regina Barzilay PhD, Ketan Badani MD FRCS and I share some insights on it’s future implementation in cancer care | St. Luke's University Health Network | Massive Bio | Massachusetts Institute of Technology | Mount Sinai Health System #AI #cancer

Great representation of @mystlukes at @LmsaNational NE 2025 meeting!! Appreciate the invitation to hopefully inspire future generations of physicians. Even better when Dr. Israel Zighelboim as faculty! #stlukesproud @MassiveBio | @TUMedResearch @TempleUniv #AI

LIVE today discussing the urgent challenges in cancer research and clinical trials due to funding cuts. AI, innovation, & collaboration are key to overcoming these obstacles and driving progress in the field. @MassiveBio
Tune in now for key insights! 🎥👇
📺 Watch live: www.youtube.com/watch?v=ar5q...

An Open Letter to Cancer Centers, Research Institutions, and the Broader Oncology Community February 2025 Dear Colleagues, In light of the recent developments regarding the The National Institutes of Health’s (NIH) abrupt reduction of indirect cost rates—from historical levels approaching 50...

NIH funding cuts threaten clinical trials and patient access to life-saving treatments. Our Co-Founder & CMO, @drbonillaonc.bsky.social, shares how we can adapt and innovate.

Read the open letter 👉 bit.ly/3CyOtnP

#Cancer #cancerclinical #clinicaltrials #OpenLetter

Massive Bio remains committed to accelerating cancer research and expanding clinical trial access amid the uncertainty surrounding recent NIH funding cuts.

The mission to ensure equitable access to innovative cancer care is more critical than ever.

Read the full press release: bit.ly/3CIRXEg

Artificial Intelligence in Cancer Care and Clinical Trials Arturo Loaiza-Bonilla, MD, discusses artificial intelligence in cancer care and clinical trials.

www.onclive.com/view/artific... This is a long format grand rounds video for OncLive where I share about the advent of #ArtificialIntelligence in #CancerCare and #ClinicalTrials - hope you find it interesting @massive-bio.bsky.social

The potential for LLMs to enhance medical training and practice is undeniable. As these models become integrated into our healthcare systems, our role as physicians is poised to evolve dramatically. Some thoughts at our ‘Practical AI’ Medscape WebMD column!! @massive-bio.bsky.social #futureofwork

The Rise of Large Language Models in Medicine: The Next Frontier In his latest column, Arturo Loaiza-Bonilla, MD, MSEd, explores the latest on large language models in medicine and the new era of medical training and practice.

#AI #LLM #medicaleducation www.medscape.com/viewarticle/...

Proud to be in California at the AMA/RUC meeting, representing American Society of Clinical Oncology (ASCO) and all U.S. oncology practices to champion equitable access and fair reimbursement for lifesaving cancer therapies. Thank you to our dedicated ASCO staff for your hard work, and to SLUHN!

Proudest moment for Massive Bio on being recognized by The White House Cancer Moonshot for our efforts in helping cancer patients to transform access clinical trials with our AI-enabled platform and scalable pre-screening hubs. Massive thank you to team and all our partners who make this possible!!

Fascinating fire chat with @bryan_johnson during our Scrub Capital mtg. Kudos to being bold investing in efforts to understand longevity, epigenetic, biomarkers, aging clocks, human physiology. At @MassiveBio we are taking also a bold innovative approach to transform clinical trials & research!! 🚀

Starting 2025 with site visits across our 15-hospitals at @mystlukes and an interview at @WNEP to discuss Surgeon General’s report on the link between alcohol and cancer risks. Committed to awareness and collaboration for screening and access @AmericanCancer - @ASCO - @MassiveBio
lnkd.in/e9MwVQhd

Happy New Year from OncoAlert

@aftimosp.bsky.social
@coffeemommy.bsky.social
@drjnaidoo.bsky.social
@agerikssonmd.bsky.social
@jackwestmd.bsky.social
@raalbany.bsky.social
@drbonillaonc.bsky.social
@stephenvliu.bsky.social
@darcyburbage.bsky.social
@itsnotpink.bsky.social

Strategies December 2024 OLP

“AI, coupled with innovative treatment approaches, will continue to drive us toward this vision”
Thank you Strategies Magazine for letting me share a techno-optimist view of cancer care in 2034!! #AI #clinicaltrials #cancerresearch #DCT bluetoad.com/publication/...

“Imagine a world where every patient, regardless of geography or socioeconomic status, has access to the best treatment options available – a world where a diagnosis does not come with a stigma or an expiration date, but rather with hope and personalized pathways to wellness”